Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 3;10(3):391.
doi: 10.3390/biom10030391.

Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts

Margaux Teil  1   2 , Marie-Laure Arotcarena  1   2 , Emilie Faggiani  1   2 , Florent Laferriere  1   2 , Erwan Bezard  1   2 , Benjamin Dehay  1   2
Affiliations
Review

Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts

Margaux Teil et al. Biomolecules. .

Abstract

Parkinson's Disease (PD) is characterized both by the loss of dopaminergic neurons in the substantia nigra and the presence of cytoplasmic inclusions called Lewy Bodies. These Lewy Bodies contain the aggregated α-synuclein (α-syn) protein, which has been shown to be able to propagate from cell to cell and throughout different regions in the brain. Due to its central role in the pathology and the lack of a curative treatment for PD, an increasing number of studies have aimed at targeting this protein for therapeutics. Here, we reviewed and discussed the many different approaches that have been studied to inhibit α-syn accumulation via direct and indirect targeting. These analyses have led to the generation of multiple clinical trials that are either completed or currently active. These clinical trials and the current preclinical studies must still face obstacles ahead, but give hope of finding a therapy for PD with time.

Keywords: Parkinson’s disease, α-synuclein; aggregation; neurodegeneration; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pringsheim T., Jette N., Frolkis A., Steeves T.D. The prevalence of Parkinson’s disease: A systematic review and meta-analysis. Mov. Disord. 2014;29:1583–1590. doi: 10.1002/mds.25945. - DOI - PubMed
    1. Jankovic J. Parkinson’s disease: Clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry. 2008;79:368–376. doi: 10.1136/jnnp.2007.131045. - DOI - PubMed
    1. Poewe W., Seppi K., Tanner C.M., Halliday G.M., Brundin P., Volkmann J., Schrag A.E., Lang A.E. Parkinson disease. Nat. Rev. Dis. Primers. 2017;3:17013. doi: 10.1038/nrdp.2017.13. - DOI - PubMed
    1. Spillantini M.G., Schmidt M.L., Lee V.M.Y., Trojanowski J.Q., Jakes R., Goedert M. α-Synuclein in Lewy bodies. Nature. 1997;388:839–840. doi: 10.1038/42166. - DOI - PubMed
    1. Shahmoradian S.H., Lewis A.J., Genoud C., Hench J., Moors T.E., Navarro P.P., Castano-Diez D., Schweighauser G., Graff-Meyer A., Goldie K.N., et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 2019;22:1099–1109. doi: 10.1038/s41593-019-0423-2. - DOI - PubMed

Publication types